Table 1.
Characteristics of selected inflammatory bowel diseases patients before and during the azathioprine treatment. Responder means patients with endoscopic mucosal healing; non-responder means patients with no endoscopic mucosal healing.
| Measured | In IBD group | Responder | Non responder | p |
|---|---|---|---|---|
| Number of the patients | 120 patients | 37% (44 patients) | 63% (76 patients) | |
| Patients with CUC | 37.50% (45 patients) | 42.20% (19 patients) | 57.8% (26 patients) | P=0.328 |
| Patients with CD | 62.50% (75 patients) | 33.30% (25 patients) | 66.70% (50 patients) | |
| % male in IBD | 60% (72 patients) | 27.80% (18 patients) | 72.20% (54 patients) | P=0.013 a |
| Age at the IBD diagnosis (years) | 36.9 ± 12.3 (median:36.5, range: 11–72) | 38.1 ± 12.3 (median: 39.5, range: 17–58) | 36.1 ± 12.4 (median: 35, range: 11–72) | P=0.049 a |
| Duration, prior to the azathioprine therapy (months) | 39.8 ± 52.5 (median: 24, range: 0–264) | 56.2 ± 69.2 (median: 24, range: 0–264) | 30.4 ± 37.1 (median: 17.5, range: 0–204) | P=0.147 |
| Duration of azathioprine used (months) | 31.5 ± 24.7 (median: 25.5, range: 4–113) | 31 ±2 5.7 (median: 24, range: 4–90) | 31.7 ± 24.3 (median: 26.5, range: 4–113) | P=0.933 |
| IBD related surgery % prior to the azathioprine therapy | 20% (24 patients) | 33.30% (8 patients) | 66.70% (16 patients) | P=0.705 |
| IBD related surgery % during the azathioprine therapy (intestinal resection) | 13.30% (16 patients) | 12.50% (2 patients) | 87.50% (14 patients) | P=0.031a |
P<0.05 was statistically significant. IBD: Inflammatory bowel diseases; CUC: Chronic ulcerative colitis; CD: Crohn’s disease.